Effect of obesity on constant workrate exercise in hyperinflated men with COPD by Laviolette, Louis et al.
RESEARCH ARTICLE Open Access
Effect of obesity on constant workrate exercise in
hyperinflated men with COPD
Louis Laviolette
1, Francesco Sava
1, Denis E O’Donnell
2, Katherine A Webb
2, Alan L Hamilton
3, Steven Kesten
4,
François Maltais
1*
Abstract
Background: Chronic obstructive pulmonary disease (COPD) and a high body mass index (BMI) can both affect
pulmonary volumes as well as exercise tolerance, but their combined effect on these outcomes is not well known.
The aim of this study was to investigate the effects of increased BMI during constant workrate cycle ergometry in
patients with COPD.
Methods: Men with COPD and hyperinflation were divided according to World Health Organization BMI
classification: 84 normal BMI (NBMI), 130 overweight (OW) and 64 obese (OB). Patients underwent spirometric and
lung volumes assessment and an incremental cycling exercise test. This was followed by a constant workrate
exercise test (CET) at 75% of peak capacity. Inspiratory capacity and Borg dyspnea scores were measured at
baseline, during and at the end of CET.
Results and discussion: FEV1 % predicted was not different across BMI classes. Total lung capacity and functional
residual capacity were significantly lower in OB and OW compared to NBMI patients. Peak VO2 in L·min
-1 was
significantly higher in OB and OW patients than in NBMI patients. CET time was not different across BMI classes
(p = 0.11). Changes in lung volumes and dyspnea during CET were not different between BMI categories.
Conclusions: OB and OW patients with COPD had a higher peak VO2 than their lean counterparts. Endurance
time, dyspnea and changes in lung volumes during CET were similar between BMI categories.
Background
COPD is characterized by reduced exercise tolerance
[1], which is determined by a multitude of factors whose
individual contribution may vary between patients[2].
Obesity is now an important issue in COPD: it is
reported in 18% [3] to 54% [4] of patients with COPD
and is associated with a better prognosis[5,6]. Both con-
ditions, when taken individually, are characterized by
physiological alterations in breathing mechanics along
with functional limitations. The precise combined effects
of COPD and obesity on such a multidimensional issue
as exercise tolerance remain ambiguous. Clinical experi-
ence dictates that their combination would lead to a
worsening of functional limitations and symptoms[7,8].
However, there are complex interactions between the
two conditions that could mitigate a negative synergic
effect on exercise performance.
On one hand, obesity is associated with an increased
work of breathing [9], increased breathing resistive load
[10] and worse exertional dyspnea [11]; combined with
COPD, these factors would likely increase demands on
an already stressed respiratory system and further
reduce exercise tolerance. On the other hand, it is asso-
ciated with decreased resting [12] and dynamic [13]
lung volumes. Given the importance of dynamic hyper-
inflation in determining exercise tolerance in COPD
[14], a reduction in lung volumes could lead to an
increased exercise tolerance. Ora et al. [15] showed that
because obese patients with COPD breathed at lower
lung volumes during incremental cycling exercise, the
perception of dyspnea at a given VE was reduced, allow-
ing for greater peak VO2 power output during incre-
mental cycling exercise.
The current study extends previous work by examin-
ing, for the first time, the impact of a broader range of
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severe obesity) on dyspnea and exercise endurance in a
large population of hyperinflated men with COPD,
whose airway obstruction varied from moderate to very
severe. This information is relevant, given that over-
weight patients likely represent a substantial proportion
of patients with an increased BMI. We also wish to eval-
uate the effects of overweight and obesity on the perfor-
mance to constant workrate cycling exercise, an exercise
testing modality that is gaining popularity to evaluate
outcomes in COPD clinical trials[16].
The general aim of this study was to investigate the
effects of increased BMI during constant workrate cycle
ergometry. We hypothesized that, despite potentially
worse exertional dyspnea and cost of breathing,
increased BMI in association with COPD would be asso-
ciated with preserved constant workrate exercise time
because of lower resting hyperinflation, which provides
a mechanical advantage on respiratory mechanics. The
specific objectives of this study were: 1) to evaluate the
effects of increased BMI on endurance time during con-
stant workrate cycle ergometry; 2) to investigate the
effect of increased BMI on operational lung volumes
during exercise; 3) to investigate the effects of BMI on
oxygen consumption, ventilation and symptoms inten-
sity during constant workrate exercise.
Methods
Study subjects and design
This study is a pooled retrospective analysis of the base-
line exercise data (prior to any pharmacological inter-
vention) from two multicentre clinical trials examining
the effects of tiotropium on exercise tolerance[17,18].
Local ethics committees approved the studies and all
subjects signed written informed consent at the time of
their assessment. For the purpose of the present study,
only men were selected in order to minimize possible
gender influence on lung volumes and exercise toler-
ance[19]. Three hundred and thirty five men with
COPD were initially included in these two studies. Ori-
ginal inclusion criteria were: age 40 to 75 years, cigarette
smoking > 10 pack-years, forced expiratory volume
(FEV1) ≤ 65% predicted, and functional residual capacity
( F R C )m e a s u r e db yb o d yp l e t h y s m o g r a p h y≥ 120% pre-
dicted. Patients with a history of asthma, allergic rhinitis
or atopy were not eligible for the trial. Moreover,
patients with any recognized contraindication to clinical
exercise testing and patients who had participated in a
rehabilitation program for COPD within 6 weeks prior
to the screening visit were also not eligible. No patients
participated in both original studies. For the present
analysis, three inspiratory capacity (IC) data points or
more (one at rest, one at submaximal exercise and one
at end-exercise) during the constant workrate endurance
test were necessary to examine changes in lung volume
during exercise. Because IC maneuvers were performed
at two-minute intervals, only patients with a constant
workrate endurance time ≥ 4 minutes (n = 278) were
included in the present analysis. Patients were classified
according to BMI classification of the World Health
Organization [20] into normal BMI (BMI 18.5 - 24.99
kg·m
-2), overweight (25 - 29.99 kg·m
-2) and obese (> 30
kg·m
-2). Ideal weight was computed according to
Wasserman et al.[21]
Baseline lung function, lung volumes and incremental
exercise testing were performed during an initial screen-
ing visit. During a subsequent 2-3 week “run-in” phase
to familiarize patients with testing procedures, they per-
formed one constant workrate cycle exercise test (CET)
o nt w oo c c a s i o n s ,w i t h o u ta n y pharmacological inter-
vention. Results of the second test were used in the pre-
sent analysis.
Lung function evaluation
Spirometry and body plethysmography were performed
according to the recognized standards[22-24]. FEV1,
forced vital capacity (FVC), FEV1/FVC, FRC, total lung
capacity (TLC) and residual volume (RV) values were
then compared to the predicted values[22]. Predicted IC
was calculated by subtracting the predicted values of
FRC from the predicted value of TLC. Maximal volun-
tary ventilation (MVV) was calculated by multiplying
FEV1 by 35[25]. Values for predicted DLCO were com-
puted according to Cotes et al.[26]
Exercise testing
The specific details of the incremental exercise test and
the CET have previously been reported[17,18]. The
incremental exercise test started with 3 min of unloaded
pedaling after which workrate was increased in stepwise
increments of 10 W·min
-1 from a starting point of
10 W. Subjects were instructed to cycle until symptom
limitation. Peak work capacity (Wpeak) was defined as
the highest workrate sustained for at least 30s. Reference
values from Jones et al.[27] were used for peak exercise
testing.
The CET started with 1 min of unloaded pedaling and
workload was set at 75% of maximal capacity. Patients
were instructed to cycle until symptom limitation at a
pedaling rate of 50-70 rpm. Ventilatory and gas
exchange parameters were collected breath-by-breath
during exercise using commercially available cardiopul-
monary exercise testing equipment. Values were
recorded at rest and during the third 30-s period of
each 2-min interval during exercise. End-exercise values
were recorded as the average of the last 30 s of exercise.
At rest, during each 2-min interval during exercise and
at the end of exercise, subjects rated the intensity of
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scale [28] and then performed an IC maneuver. The IC
was used to track changes in operating lung volumes
during exercise as previously described[29]. Oxygen
pulse saturation (SpO2) was monitored during exercise.
Statistical analysis
Results are shown as mean ± SD unless otherwise speci-
fied. Results are expressed as five time points: for each
subject, data obtained at baseline, 25%, 50%, 75% and
100% of endurance time were used in the analysis. For
continuous variables, BMI categories (normal BMI, over-
weight and obese) were compared first using ANOVAs.
If statistical significance was reached, pairs were com-
pared using Tukey-Kramer’s HSD. The rate of hyperin-
flation during the constant workrate cycle exercise test
(CET) was calculated by dividing the fall in IC by
elapsed CET time. Statistical significance was set at
p < 0.05.
Results
Patient’s characteristics and static lung volumes
Table 1 shows patient characteristics according to BMI
class. There were 84 male patients with normal BMI
(BMI range: 18.62 - 24.96 kg/m
2), 130 overweight
patients (BMI range: 25.06 -29.86 kg/m
2) and 64 obese
patients (BMI range: 30.06 - 41.96 kg/m
2). FEV1 and
FVC were not significantly different between BMI
classes. Resting lung volumes were significantly reduced
in obese compared to normal weight patients.
Exercise tolerance
Peak VO2 (L·min
-1, % predicted and according to ideal
body weight) was significantly increased, from normal
BMI to obese patients. Figure 1 shows that CET time
was not statistically different between the three groups
(p = 0.11).
Dynamic lung volumes
Figure 2 shows dynamic lung volumes during the CET
expressed as a % of predicted TLC. Obesity significantly
reduced end-expiratory lung volume (EELV) and end-
inspiratory lung volume (EILV) at rest and at 50% and
100% of CET time. However, IC (% of predicted TLC),
tidal volume (VT, % of predicted TLC), and inspiratory
lung volume (IRV, % of predicted TLC) were not signifi-
cantly different between BMI categories at any time
points during the CET. The total decrease in IC during
CET was 421 ± 409, 462 ± 389 and 380 ± 487 ml, for
normal BMI, overweight and obese respectively (p =
0.46). The rate of fall in IC was not significantly differ-
ent between BMI categories: -0.83 ± 0.90, -0.96 ± 0.80
and -0.81 ± 1.14 ml·s
-1, for normal BMI, overweight and
obese respectively (p = 0.52).
Breathing pattern and VO2
Figure 3 shows VO2 and breathing pattern during CET
for all three BMI classes. VO2 (L&183;min
-1) was higher
as BMI increased at all time points during the CET,
except at rest. When expressed in % of peak value
attained during the incremental exercise test, VO2 was
not significantly different between groups. Ventilation
(VE), VT and respiratory rate (RR) were not significantly
different across BMI classes during the CET. SpO2
showed significantly lower values during the CET in
obese and overweight patients.
Dyspnea and leg discomfort
Time courses of dyspnea and leg discomfort during the
CET (figure 4) were not significantly different across
BMI classes. The dyspnea/VO2 ratio was shifted to the
right with increasing BMI. As BMI increased, the steep
rise in Borg dyspnea score occurred at higher VO2
(L·min
-1). However, for a same value of VE (L·min
-1) and
IRV (% of predicted TLC), dyspnea was similar across
the three BMI categories.
Discussion
This study takes advantage of a unique exercise test-
ing database in COPD to investigate the impact of
obesity on constant workrate exercise tolerance and
dynamic lung volumes in a large sample of male
patients with COPD and resting lung hyperinflation.
The main study results are as follows: 1) resting
hyperinflation is reduced in the presence of increased
BMI despite similar FEV1, 2) obesity is associated
with higher incremental peak exercise VO2 while CET
time was not statistically different across BMI cate-
gories, 3) absolute dynamic lung volumes (EELV,
EILV) during the CET were reduced as BMI
increased, but the overall rate of dynamic hyperinfla-
tion was similar across BMI categories, and 5) dys-
pnea ratings during the CET were not significantly
different across BMI categories.
In this sample, obesity, compared to normal BMI, was
associated with reduced resting hyperinflation and gas
trapping. These results are consistent with observations
in otherwise healthy subjects showing a significant redu-
cing effect of increased BMI on static pulmonary
volumes[12,13,30-32]. Our results are also similar to
those of a previous mechanistic study investigating the
effects of obesity in COPD on exertional dyspnea [15],
indicating that the lung deflating effect of obesity is pre-
sent in COPD, irrespective of the level of airway
obstruction, which ranged from moderate to very severe.
We submit that the added thoracic and abdominal
weight in obese patients with COPD leads to decreased
respiratory system compliance and to a reduction in
static hyperinflation.
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lower, but that tidal volume and inspiratory capacity
were unchanged in obese patients with COPD. Interest-
ingly, extending the results of Ora et al. [15] we con-
firmed that the rate and extent of dynamic pulmonary
hyperinflation was not influenced by BMI across the
range from overweight to severe obesity in a large popu-
lation of patients with varying FEV1.
Dynamic lung volumes are subjected to multiple
forces in patients with COPD with increased BMI.
While resting hyperinflation was reduced in overweight
and obese patients, the variations in EELV during exer-
cise across BMI groups were not different. In men with
normal lung function, the effects of obesity vary with
the intensity of exercise, with lower intensities eliciting
lung deflation and higher intensities, increases in
Table 1 Baseline characteristics
Normal BMI (NBMI), n = 84 Overweight (OW), n = 130 Obese (OB), n = 64 p
NBMI OW NBMI
Mean (SD) Mean (SD) Mean (SD) vs. vs. vs.
OW OB OB
Age, years 61.4 (7.2) 62.6 (6.4) 61.6 (6.6) - - -
Tobacco exposure, Pack*years 52.3 (25.7) 59.0 (29.6) 55.8 (25.5) - - -
BMI, kg*m
-2 22.5 (1.7) 27.3 (1.5) 33.4 (3.1) 0.0001 0.0001 0.0001
Ideal weight, kg 77.6 (0.6) 77.9 (0.5) 76.9 (0.7) - - -
FEV1, L 1.31 (0.39) 1.35 (0.45) 1.42 (0.49) - - -
% predicted 40 (11) 42 (13) 44 (14) - - -
FVC, L 3.09 (0.81) 3.04 (0.80) 2.89 (0.78) - - -
% predicted 75 (18) 74 (17) 71 (17) - - -
FEV1/FVC 42.9 (8.6) 44.5 (10.1) 48.9 (11.7) - 0.05 0.01
TLC 8.38 (1.27) 8.04 (1.27) 7.79 (1.14) - - 0.05
% predicted 121 (17) 116 (17) 114 (14) - - 0.05
IC, L 2.46 (0.57) 2.51 (0.60) 2.50 (0.65) - - -
% predicted 73 (15) 75 (17) 76 (18) - - -
IC/TLC 30 (7) 31 (7) 32 (8) - - -
FRC, L 6.06 (1.16) 5.66 (1.10) 5.40 (1.05) 0.05 - 0.001
% predicted 170 (31) 158 (29) 152 (27) 0.05 - 0.001
RV, L 5.02 (1.26) 4.63 (1.16) 4.53 (0.99) - - 0.05
% predicted 208 (50) 188 (50) 185 (46) 0.05 - 0.05
DLCO, ml*mmHg
-1*min
-1 15.4 (5.1) 16.2 (5.5) 19.2 (6.6) - 0.01 0.001
% predicted 46 (22) 48 (24) 59 (27) - 0.01 0.01
Incremental exercise test
Peak VO2, L*min
-1 1.204 (0.385) 1.375 (0.379) 1.550 (0.450) 0.01 0.05 0.0001
ml*kg
-1*min
-1 17.5 (5.3) 16.3 (4.0) 15.4 (4.4) - - 0.05
% predicted 50 (15) 57 (14) 65 (18) 0.01 0.01 0.0001
ml*kgideal weight
-1*min
-1 15.5 (4.7) 17.5 (4.8) 20.2 (5.6) 0.01 0.01 0.0001
Peak VE, L*min
-1 44.5 (13.8) 48.5 (13.5) 49.2 (14.3) - - -
% MVV 100.3 (32.2) 108.6 (32.9) 108.0 (39.1) - - -
Peak power, W 82.8 (28.1) 90.4 (26.7) 93.2 (35.1) - - -
% predicted 45 (14) 50 (15) 52 (18) - - 0.05
Values are mean (SD), min - max. Definition of abbreviations: BMI: body mass index, FEV1 : forcedexpiratory volume in 1 second, FVC: Forced vital capacity, TLC:
total lung capacity, IC: inspiratory capacity, FRC: functional residual capacity, RV: residual volume, DLCO: dilution capacity for carbon monoxide.
Figure 1 Constant workrate cycle exercise performance (s)
according to body mass index categories. Values are mean ± SE.
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exercise was in part explained by the need to escape
flow limitation as ventilation increased[31]. In the pre-
sent study, flow-volume curves were not available to
objectify flow limitation during exercise; however, given
that the three groups behave almost identically in terms
of dynamic hyperinflation irrespective of BMI, we sub-
mit that COPD was the main driving factor for dynamic
lung volumes.
Increasing BMI over a wide range did not emerge as a
disadvantage with respect to endurance time to toler-
ance at a standardized workload, when compared with
their normal BMI counterparts. However, the design of
constant workrate cycling exercise, while offering large
sensitivity to interventions, may introduce some bias
when comparing inter-patient performance. In our
study, obese patients reached higher absolute and rela-
tive peak VO2. Therefore, they exercised at a higher
absolute VO2 during CET. However, VO2. during the
CET, expressed as a percentage of VO2 during the
incremental test, was not significantly different between
BMI categories Therefore, the relative intensity of the
CET was uniform across BMI categories.
In theory, breathing at lower operating lung volumes
should place the respiratory muscles (particularly the
diaphragm) in a more favorable position to generate
t e n s i o na n dt h e r e f o r em i t i g a t es o m eo ft h en e g a t i v e
mechanical and metabolic consequences of COPD dur-
ing exercise. The net effect of combining higher BMI
with COPD was not disadvantageous during cycle exer-
cise (compared with normal BMI COPD): the change in
dyspnea as a function of time or VE across the three
BMI categories (figure 4) was similar. The VE/MVV
relationships were also strikingly similar across the three
BMI categories (figure 3). The fact that CET time was
not decreased in obese patients can be easily understood
when considering the absence of notable difference in
t h et i m ec o u r s e so fd y s p n e aa n dV E between BMI cate-
gories. At variance with our results, Ora and colleagues
reported that dyspnea per unit VE was lower in obese
compared to lean patients with COPD[33]. This differ-
ence between studies can be explained, in part, by the
exercise protocol used (constant work rate in the pre-
sent study versus incremental in Ora’s study). Also,
Ora’s study was ideally suited to highlight the impact of
obesity on the dyspnea/VE relationship because the dif-
ferences in lung volumes between BMI categories were
important and larger than in the present study.
Limitations of the study
Because the present study involved a large sample size, a
wide range of disease severity and was rigorously con-
ducted in experienced research centers, we feel confi-
dent about the validity of the conclusions set forth.
However, measurements made in this study did not
allow us to investigate the mechanisms involved in
dynamic hyperinflation. One limitation is that patients
with COPD were not phenotyped as a part of this study.
I tm i g h tb ea r g u e dt h a tt h eproportion of emphysema-
tous patients might have been greater in those with nor-
mal BMI. However, recent observations do not support
this traditional theory. The correlation between BMI
and the severity of emphysema is weak [34] and a recent
sub-analysis of the NETT trial, in which computed
tomography was performed to confirm emphysema,
showed that the mean BMI of emphysematous patients
was 24.6 ± 3.6, well within normal range and on the
verge of overweight[35].
Figure 2 Operating lung volumes during constant workrate cycle exercise expressed as a % of predicted total lung capacity
according to body mass index categories. Panel A shows end-inspiratory lung volume (EILV) and panel B, end-expiratory lung volume (EELV).
Data points represent mean values at baseline, 25%, 50%, 75% and 100% of constant workrate endurance time. Values are mean ± SE. White
filled circles are normal BMI, grey are overweight and black, obese patients. Horizontal lines represent total lung capacity for normal BMI (NBMI),
overweight, (OW) and obese (OB) patients. * = p < 0.05; † = p < 0.005; ‡ = p < 0.01.
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Page 5 of 9Figure 3 Oxygen consumption (VO2,L · m i n
-1 [panel A] and as a % of peak incremental values [panel B]) during constant workrate
exercise (CET), ventilation (VE, L·min
-1 [panel C] and as a % of MVV [panel D]), tidal volume (VT, ml [panel E) and as a % of vital
capacity [panel F]), respiratory rate (RR, breaths·min
-1) and O2 pulse saturation (SpO2) in relation to constant workrate endurance time
(s). Values are mean ± SE. White filled circles are normal BMI, grey are overweight and black, obese patients. * = p < 0.0001; † = p < 0.01;
‡ = p < 0.001.
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Page 6 of 9Figure 4 Borg dyspnea (panel A) and leg fatigue (panel B) scores in relation to constant workrate endurance time, Borg dyspnea
score in relation to oxygen consumption (VO2, L·min
-1, panel C) ventilation (VE, L·min
-1, panel D) and inspiratory reserve volume (IRV,
% of predicted total lung capacity, panel E). Values are mean ± SE. White filled circles are normal BMI, grey are overweight and black, obese
patients.
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> 120% as an entry criteria. This requirement for hyper-
inflation could have attenuated the difference in exercise
performance between BMI categories. Also, since
patients were selected to have significant hyperinflation,
the effects of obesity on COPD with less severe hyperin-
flation are unknown. Because of the potentially different
mechanisms of hyperinflation between men and women
[19], these results might not be applicable to obese
women with COPD. Lastly, as BMI does not provide
information on fat distribution, it would be of interest to
investigate whether central versus peripheral obesity
exert similarly influence on the exercise response.
Conclusions
Increased BMI was associated with an increased peak
incremental VO2 while endurance to constant workrate
cycling exercise at the same relative intensity was similar
across BMI categories. Static and dynamic lung volumes
were reduced as BMI increased. Despite this, the rate of
change in lung volumes during exercise was not modi-
fied in overweight and obese COPD. Exertional dyspnea
was not significantly different across BMI categories.
Overall, the effect of obesity in male patients with
COPD and hyperinflation was not disadvantageous in
terms of exercise endurance and exertional dyspnea dur-
ing constant workrate cycling exercise.
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